GlassScriptPhysician profile
Peter L Christensen
NPI 1992737159
$10,416.23
in general payments reported to CMS, 2019-2025
60 companies · $1,503 in 2025
The $1,503 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,535 · 2020: $1,273 · 2021: $1,514 · 2022: $1,403 · 2023: $1,913 · 2024: $1,275 · 2025: $1,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,442 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,441.74 |
| Education | $249.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,479.48 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $773.08 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.97 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $720.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $609.01 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $581.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $560.94 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $488.25 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $448.87 | 2019-2024 | Xarelto |
| Amgen INC. | $412.32 | 2020-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $403.14 | 2019-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Abbott Laboratories | $282.91 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $241.93 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $219.76 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $218.74 | 2019-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.